Regeneron Pharmaceuticals Inc. Stock Falls 4.5%, Underperforms Peers
Dow Jones2026/09/28 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. slid 4.5% to $752.25 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.8% to 7,683.69 and Dow Jones Industrial Average falling 0.7% to 51,481.51.
This was the stock's fourth consecutive day of losses.
Regeneron Pharmaceuticals Inc. closed 12.5% below its 52-week high of $859.34, which the company achieved on September 3rd.
The stock underperformed when compared to some of its peers, as Amgen Inc. rose 0.8% to $418.13, Moderna Inc. fell 0.8% to $197.28, and Gilead Sciences Inc. rose 0.85% to $152.21.
Trading volume totaled 1.1 million, compared to the 50-day average of 746,021.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 28, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
